Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells

Area of Science:

• Hematology
• Immunology
• Genetics

Background:

• Plasmacytoid Dendritic Cells (pDCs) are crucial for immune responses, producing type I interferon (IFN).
• Neoplastic counterparts include Blastic pDC Neoplasm (BPDCN) and Mature pDC Proliferation (MPDCP), with MPDCP subtypes like pDC-CMML and pDC-AML.
• Distinguishing pDC-AML from BPDCN is challenging, necessitating the exploration of genomic markers.

Purpose of the Study:

• To systematically review and compare the cytogenetic, molecular, and transcriptional characteristics of BPDCN and pDC-AML.
• To identify genomic features that can aid in the differential diagnosis of these myeloid neoplasms.
• To explore the potential diagnostic, prognostic, and therapeutic implications of these genomic findings.

Main Methods:

• Systematic review of cytogenetic, molecular, and transcriptional data for BPDCN and pDC-AML.
• Analysis of recurrent genetic rearrangements, deletions, and gene mutations.
• Comparison of genomic profiles between BPDCN and pDC-AML.

Main Results:

• BPDCN frequently exhibits complex karyotypes with recurrent MYB/MYC rearrangements and deletions in ETV6, IKZF1, RB1, and TP53.
• Mutations in epigenetic and splicing pathways, along with dysregulation of NF-kB, TCF4, BCL2, and IFN pathways, are noted in BPDCN.
• pDC-AML shows limited cytogenetic abnormalities, similar to other AML, with RUNX1 being the most frequently mutated gene (70%).

Conclusions:

• Distinct genomic profiles exist between BPDCN and pDC-AML.
• These genomic features hold potential for improving diagnostic accuracy.
• Further investigation into these genetic characteristics may offer prognostic and therapeutic insights.